A Peculiar Case of Recurrent Coronary Artery Thrombosis

Overview

Journal Cureus

Specialty Biomedical Engineering

Date 2022 Oct 28

PMID 36304350

Authors

Samuel Nwaobi

Zachary Wood

Aarushi Kalra

Sophia Nguyen

Affiliations

Soon will be listed here.

Abstract

Coronary artery thrombosis is a phenomenon physicians have studied throughout the years. The different risk factors that play a role in the formation of an atherosclerotic plaque leading to coronary artery blockage are vast and can affect the patient significantly if not examined and diagnosed carefully. The objective of this case report is to highlight this unusual occurrence of repeated coronary artery thrombosis. A 54-year-old Caucasian female presented to the emergency department with a one-day history of sharp chest pain in the substernal area that radiated between her shoulder blades and left arm. Despite being on dual antiplatelet therapy, an electrocardiogram (ECG) showed an inferior ST-elevation myocardial infarction (STEMI). Her medical history was extensive with factor V Leiden deficiency, hyperhomocysteinemia, recurrent deep vein thrombosis (DVT), and a family history of myocardial infarction. The patient was taken to the cardiac catheterization lab based on these characteristics. The patient was diagnosed with a 100% thrombosis in the distal right coronary artery (RCA), which was stented nine months before this current presentation. The patient had been compliant with all her medications from her previous stent placement. A new drug-eluting stent (DES) was inserted, and the patient was placed on prasugrel and apixaban. This was a very interesting topic for a case report due to the time frame of repeat thrombosis in a coronary artery with a DES and the patient's underlying hypercoagulable state. There are few cases of same vessel restenosis post-DES placement. Our case highlights the need for further research into the prevalence of genetic risk factors in coronary artery thrombosis and the need to investigate the efficacy of different anticoagulation therapies in patients with factor V Leiden thrombophilia.

References

Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Meneveau N . Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2008; 360(4):363-75. DOI: 10.1056/NEJMoa0808227. View

Soeki T, Tamura Y, Shinohara H, Sakabe K, Onose Y, Fukuda N . Plasma concentrations of fibrinolytic factors in the subacute phase of myocardial infarction predict recurrent myocardial infarction or sudden cardiac death. Int J Cardiol. 2002; 85(2-3):277-83. DOI: 10.1016/s0167-5273(02)00186-9. View

Bonello L, Tantry U, Marcucci R, Blindt R, Angiolillo D, Becker R . Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol. 2010; 56(12):919-33. DOI: 10.1016/j.jacc.2010.04.047. View

Hulot J, Collet J, Silvain J, Pena A, Bellemain-Appaix A, Barthelemy O . Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis. J Am Coll Cardiol. 2010; 56(2):134-43. DOI: 10.1016/j.jacc.2009.12.071. View

Valgimigli M, Bueno H, Byrne R, Collet J, Costa F, Jeppsson A . 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the.... Eur Heart J. 2017; 39(3):213-260. DOI: 10.1093/eurheartj/ehx419. View

Rosendaal F, Siscovick D, Schwartz S, Beverly R, Psaty B, Longstreth Jr W . Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. Blood. 1997; 89(8):2817-21. View

Kamran H, Jneid H, Kayani W, Virani S, Levine G, Nambi V . Oral Antiplatelet Therapy After Acute Coronary Syndrome: A Review. JAMA. 2021; 325(15):1545-1555. DOI: 10.1001/jama.2021.0716. View

Mega J, Simon T, Collet J, Anderson J, Antman E, Bliden K . Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA. 2010; 304(16):1821-30. PMC: 3048820. DOI: 10.1001/jama.2010.1543. View

Margaglione M, Brancaccio V, De Lucia D, Martinelli I, Ciampa A, Grandone E . Inherited thrombophilic risk factors and venous thromboembolism: distinct role in peripheral deep venous thrombosis and pulmonary embolism. Chest. 2000; 118(5):1405-11. DOI: 10.1378/chest.118.5.1405. View

10.

Raber L, Magro M, Stefanini G, Kalesan B, van Domburg R, Onuma Y . Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents: a prospective cohort study. Circulation. 2012; 125(9):1110-21. DOI: 10.1161/CIRCULATIONAHA.111.058560. View

11.

Patti G, Micieli G, Cimminiello C, Bolognese L . The Role of Clopidogrel in 2020: A Reappraisal. Cardiovasc Ther. 2020; 2020:8703627. PMC: 7140149. DOI: 10.1155/2020/8703627. View

12.

Angiolillo D, Ueno M, Goto S . Basic principles of platelet biology and clinical implications. Circ J. 2010; 74(4):597-607. DOI: 10.1253/circj.cj-09-0982. View

13.

Collet J, Hulot J, Pena A, Villard E, Esteve J, Silvain J . Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet. 2008; 373(9660):309-17. DOI: 10.1016/S0140-6736(08)61845-0. View

14.

van Werkum J, Heestermans A, de Korte F, Kelder J, Suttorp M, Rensing B . Long-term clinical outcome after a first angiographically confirmed coronary stent thrombosis: an analysis of 431 cases. Circulation. 2009; 119(6):828-34. DOI: 10.1161/CIRCULATIONAHA.108.799403. View

15.

Schomig A, Neumann F, Kastrati A, Schuhlen H, BLASINI R, Hadamitzky M . A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med. 1996; 334(17):1084-9. DOI: 10.1056/NEJM199604253341702. View

16.

Leon M, Baim D, Popma J, Gordon P, Cutlip D, Ho K . A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med. 1998; 339(23):1665-71. DOI: 10.1056/NEJM199812033392303. View

17.

Wiviott S, Braunwald E, McCabe C, Montalescot G, Ruzyllo W, Gottlieb S . Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007; 357(20):2001-15. DOI: 10.1056/NEJMoa0706482. View

18.

Mateo J, Oliver A, Borrell M, Sala N, Fontcuberta J . Laboratory evaluation and clinical characteristics of 2,132 consecutive unselected patients with venous thromboembolism--results of the Spanish Multicentric Study on Thrombophilia (EMET-Study). Thromb Haemost. 1997; 77(3):444-51. View

19.

Farb A, Sangiorgi G, Carter A, Walley V, Edwards W, Schwartz R . Pathology of acute and chronic coronary stenting in humans. Circulation. 1999; 99(1):44-52. DOI: 10.1161/01.cir.99.1.44. View